Last reviewed · How we verify
NM-3
At a glance
| Generic name | NM-3 |
|---|---|
| Sponsor | Genzyme, a Sanofi Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Assessing Ventilator Safety in Patients on Pressure-Support Ventilation (NA)
- Detecting Post-surgical Respiratory Compromise and Prompting Patients to Self-rescue: An Early Feasibility Study (NA)
- Feasibility and Impact of Volume Targeted Ventilation in the Delivery Room (NA)
- NiPPV in the Treatment of Acute Asthma Exacerbations (NA)
- Noninvasive Positive Airway Pressure in the Pediatric Emergency Department for the Treatment of Acute Asthma Exacerbations (NA)
- MyoRing Implantation With Corneal Collagen Crosslinking for Keratoconus (NA)
- Standard Corneal Collagen Crosslinking Versus Transepithelial Corneal Crosslinking by Iontophoresis of Riboflavin (NA)
- A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NM-3 CI brief — competitive landscape report
- NM-3 updates RSS · CI watch RSS
- Genzyme, a Sanofi Company portfolio CI